SLCO1C1

Across TCGA pan-cancer cohorts, SLCO1C1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLCO1C1 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher SLCO1C1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLCO1C1 expression acts as an unfavorable survival marker.

ESCA, ACC, and READ are the cancer types where SLCO1C1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.375	0.699	.009	24	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
READ	DFS	Median	All	0.162	0.720	.019	9	view →
LUSC	OS	Median	III,IV	0.202	0.679	.001	9	view →
STAD	OS	Median	IV	0.111	0.433	.002	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLCO1C1–ESCA (OS)

Open the ESCA breakdown →